Posted by cv6-admin
CV6 Therapeutics
Professor Patrick (Paddy) Johnston was a founding Board Member of CV6 Therapeutics and served as the Chairman of the Board of Directors from 2016 until his untimely passing in 2017. Paddy was a pioneer in the cancer research field, a truly inspirational and visionary leader who inspired those around him to ‘dream no little dreams’. […]
Posted by cv6-admin
CV6 Therapeutics
Jim Poliero is a licensed real estate broker and currently manages a private portfolio of income producing real estate, mortgages and equities. Mr. Poliero began his career with Commerce Bank (now known as TD Bank) and an affiliated real estate developer for 15 years where he served as a commercial loan officer, and specialized in […]
Posted by pbd-admin
CV6 Therapeutics
James Judson, ‘Jim’, served as a Board Member of CV6 Therapeutics from 2015 before stepping in as the Interim Chairman of the Board of Directors from June 2017 until his untimely passing on the 4th of January 2018. Jim was a trusted and valued member of the CV6 Team and will be deeply missed. We […]
Posted by pbd-admin
CV6 Therapeutics
Dr Melissa LaBonte Wilson joined the CV6 Therapeutics team in 2014 as a consultant in the biological validation of candidate small molecule inhibitors in our drug development pipeline. Melissa has over 14 years experience in the preclinical evaluation of small molecule and biologic-based cancer therapeutics having identified and characterized several first-in-class small-molecule and antibody-derived inhibitors […]
Posted by pbd-admin
CV6 Therapeutics
Dr. Lewis has over thirty years’ experience in the pharmaceutical industry discovering and developing novel small molecule and biological products for Merck & Co., and for Eisai Co., Ltd. While with Eisai, he most recently led the Pharmaceutical Sciences and Technology Core Function Unit (PST). PST performed chemical, manufacturing, and controls development at 10 sites […]
Posted by pbd-admin
CV6 Therapeutics
Dr El-Khoueiry completed his medical degree, residency in internal medicine and fellowship in hematology and oncology at the Keck School of Medicine of the University of Southern California. He is currently Assistant Professor of clinical medicine in the Division of Medical Oncology, a member of the Gastrointestinal Cancers Program and director of the phase I […]
Posted by pbd-admin
CV6 Therapeutics
Professor Wilson completed his medical degree at the Queen’s University Belfast (QUB), then worked in N. Ireland and Scotland as a junior doctor during which he engaged in three years of basic science research in colorectal cancer in QUB. He subsequently trained in clinical oncology in N. Ireland achieving UK accreditation, and then participated in […]
Posted by pbd-admin
CV6 Therapeutics
Dr Wilson, has over 19 years of experience in cancer research projects focused on identifying mechanisms to improve the effectiveness of chemotherapeutic agents in human cancers. Since 2014, he has held the position of Scientific Director of Drug Development at CV6 Therapeutics (NI) Ltd. Dr Wilson’s research has focused on cellular signaling pathways and the […]
Posted by pbd-admin
CV6 Therapeutics
Bob Comfort is the Honorary Consul, Washington State, for the Grand Duchy of Luxembourg. He was the Chief Tax Officer at Amazon.com, a position he held from 2000 until 2011. During his tenure at Amazon, the tax department grew from a staff of three professionals in Seattle to a fully capable team of nearly 100 […]
Posted by pbd-admin
CV6 Therapeutics
Karl Mulligan, PhD, has over 20 years experience in cancer research and the commercial life sciences sector. Since October 2014 he has held the position of Chief Operating Officer and Co-Founder of CV6 Therapeutics (NI) Ltd, an early stage drug development company. In addition he is an Entrepreneur in residence at the Northern Ireland Science […]
